Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study

Table 1 Exposure of pediatric patients residing in Alabama to individual TNFi and patient-years of exposure for each^a

Medication	Number of subjects exposed	Total patient-years of exposure
Adalimumab	469	495.3
Certolizumab pegol	9	2.0
Etanercept	324	194.6
Golimumab	6	1.5
Infliximab	527	840.6
All TNFi	1033	1564.3

^aBecause many subjects were exposed to more than one TNFi, the total number of subjects does not equal the sum of the subjects for the individual medications

ISSN: 1546-0096